Are you a creative problem solver and a quick learner with experience of observational research? Do you have passion and curiosity for understanding complex data and generating insights from them? Do you want to start your career at one of the world's largest pharmaceutical companies, in a team that aims to transform the way we use data and analytics to develop and deliver better medicines for patients?
Then StarTrack, a new programme in Personalised Healthcare (PHC) Data Science, is made for you! You will join the PHC Data Science team at Roche Headquarters in Basel for a period of 24 months, and work on innovative projects spanning multiple disease areas using a variety of analytic tools and data types (e.g., Electronic Medical Records, Insurance Claims, Patient-Centred Outcomes, Digital Data, Genomics, Imaging and Clinical Trial Data).
- Duration: 24 months, starting in May 2019 (some flexibility with start date)
- Location: Roche Pharmaceuticals in Basel, Switzerland
- A structured programme preparing early-in-career graduates for an industry position in Personalised Healthcare (PHC) Data Science
- Opportunities for varied, challenging and innovative projects among the different functions in Roche PHC Data Science (e.g. Real-World Data, Analytics, Omics and Imaging).
Outcome and prospects
- Develop a thorough understanding of how real-world data is used to generate meaningful real-world evidence in pharmaceutical development, regulatory approval and market access.
- Gain hands-on experience by contributing to studies using data and analytics to accelerate how Roche develops innovative medicines and sustains patient access to medicines.
- Professional development opportunities including presenting your research at conferences and participating in a variety of courses offered by the company.
- Opportunities to be involved in all aspects of our work, from conceptualisation of research ideas to study design, programming and analysis, interpretation and dissemination of results through internal presentations or publications.
Who you are
- Recent MSc/PhD university graduate (you graduated no more than 12 months ago)
- Graduate of a quantitative data science discipline (e.g. epidemiology, pharmaco-epidemiology, public health, statistics/biostatistics, bioinformatics or computer science)
- Experience of observational research required (evidence of previous experience utilising longitudinal anonymous patient-level healthcare databases preferred)
- Statistical programming skills preferred e.g. R, SAS, Python, Stata
- Proven history of publications in peer-reviewed journals, and/or abstracts (including presentations) at scientific conferences is a plus
- Limited prior experience in a pharmaceutical company (maximum 1 year)
- Fluency in written and verbal English
- Good interpersonal and presentational skills
How to apply?
Applications open from 1 September 2018 and end 21 October 2018. In order to apply please click here.
Learn more about PHC at Roche
Selection of recent publications from PHC Data Science
Davies, J., Martinec, M., Delmar, P., Coudert, M., Bordogna, W., Golding, S., Martina, R., and Crane, G. (2018). Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. J. Comp. Eff. Res.
Bhutani, T., Abrouk, M., Sima, C.S., Sadetsky, N., Hou, J., Caro, I., Chren, M.-M., and Arron, S.T. (2017). Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J. Am. Acad. Dermatol. 77, 713–718.
Curtis, M.D., Griffith, S.D., Tucker, M., Taylor, M.D., Capra, W.B., Carrigan, G., Holzman, B., Torres, A.Z., You, P., Arnieri, B., et al. (2017). Development and Validation of a High-Quality Composite Real-World Mortality Endpoint. Health Serv. Res. 0.
Davies J, Patel M, Gridelli C, De Marinis F, Waterkamp D, McCusker ME. (2017) Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. PloS one. 2017 Apr 14;12(4):e0175679.
Houghton, R., Ong, R.C., and Bolognani, F. (2017) Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Res. 10: 2037-2047. doi:10.1002/aur.1848.
Kim, S.C., Solomon, D.H., Rogers, J.R., Gale, S., Klearman, M., Sarsour, K., and Schneeweiss, S. (2017) Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 69, 1154–1164.
Krueger, W.S., Anthony, M.S., Saltus, C.W., Margulis, A.V., Rivero-Ferrer, E., Monz, B., Hirst, C., Wormser, D., and Andrews, E. (2017). Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis. Drugs - Real World Outcomes 4, 139–149.
Willis, J., Morse, L., Vitale, S., Parke, D.W., Rich, W.L., Lum, F., and Cantrell, R.A. (2017). Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry. Ophthalmology 124, 935–943.
Brandon Arnieri, Coen Bernaards, Kenneth Wilhelm, James Black, Ceri Hirst, Michael Taylor, Peter Lambert, Kathryn Green, Michael Lu, Kathryn Humphrey (2016) Changing Demographics and Treatment Patterns in Patients the United States with Chronic Lymphocytic Leukemia in the First-Line Setting As Assessed Using a Novel Electronic Health Record Database Blood Dec 2016, 128 (22) 4787.